Skip to main content
Medical information Clinical review pending

Cytogenetics

Immunohistochemistry Cytokeratin 19 CK19 Test

The Immunohistochemistry Cytokeratin 19 (CK19) Test helps identify specific cancer markers in tumor tissues, aiding in the diagnosis and management of certain cancers like lung and breast cancer.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Tumor tissue sample, either in 10% Formal-saline or Formalin fixed paraffin embedded block.
Results
Confirm with the laboratory before booking.
Preparation
Submit tumor tissue in 10% Formal-saline or Formalin fixed paraffin embedded block. Provide a copy of the Histopathology report, site of biopsy, and clinical history.
Test priceKSh 7,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Immunohistochemistry Cytokeratin 19 CK19 Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of epithelial cancers
  • ✓Assessment of tumor aggressiveness
  • ✓Prognosis determination
  • ✓Guidance for treatment planning
  • ✓Evaluation of abnormal tissue findings
  • ✓Investigation of symptoms suggestive of epithelial cancer
02

In plain language

What this test helps you understand

Aids in the diagnosis, prognosis, and treatment planning for certain epithelial cancers by detecting the presence and expression level of Cytokeratin 19 in tumor tissue.
The Immunohistochemistry Cytokeratin 19 (CK19) Test is a specialized diagnostic tool used primarily in oncology. It detects the presence of Cytokeratin 19, a protein found in epithelial cells. This test is instrumental in identifying certain types of cancers, particularly those arising from epithelial tissues. By utilizing immunohistochemistry techniques, this test provides valuable insights into tumor characteristics, helping healthcare professionals make informed decisions regarding treatment options.

This test specifically measures the expression of Cytokeratin 19 in tumor tissue samples. Elevated levels of CK19 can indicate the presence of malignancies and help in assessing tumor aggressiveness. By analyzing the staining patterns and intensity, pathologists can determine the likelihood of cancer spread and the appropriate therapeutic approach.

Individuals who may benefit from this test include those with abnormal tissue findings on imaging studies, symptoms suggestive of epithelial cancers (like unexplained weight loss, persistent cough, or unusual lumps), or a family history of certain cancers. Consultation with an oncologist or pathologist is recommended to determine the appropriateness of this test.

The Immunohistochemistry Cytokeratin 19 CK19 Test offers benefits such as early cancer detection, assistance in diagnosing tumors, guidance in treatment planning, and providing prognostic information. Results are interpreted alongside clinical findings and other tests. Your doctor will explain the implications of your results.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationSubmit tumor tissue in 10% Formal-saline or Formalin fixed paraffin embedded block. Provide a copy of the Histopathology report, site of biopsy, and clinical history.
SampleTumor tissue sample, either in 10% Formal-saline or Formalin fixed paraffin embedded block.
MethodologyImmunohistochemistry (IHC) using antibodies specific to Cytokeratin 19.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects the presence of CK19, which is not exclusive to cancer and can be found in some non-cancerous conditions. Results must be interpreted by a qualified pathologist in conjunction with other clinical information.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Cytokeratin 19 (CK19) is a protein found in epithelial cells, which line the surfaces of organs and cavities in the body. Its presence can be a marker for certain types of cancer.
This test helps doctors identify and characterize certain types of cancer, particularly those originating from epithelial tissues, like lung or breast cancer. It aids in diagnosis and treatment planning.
A sample of the tumor tissue is required. This can be a formalin-fixed paraffin-embedded block or a tissue biopsy sample.
Turnaround time varies depending on the sample type and laboratory workload. Please confirm the current turnaround time with the laboratory before booking.
A qualified pathologist interprets the results of the Immunohistochemistry CK19 test. They will consider the staining patterns and intensity in the context of your clinical information.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp